Equities

Laekna Inc

Laekna Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)13.76
  • Today's Change0.46 / 3.46%
  • Shares traded16.65m
  • 1 Year change-42.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 06:41 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-317.77m
  • Incorporated2016
  • Employees92.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CARsgen Therapeutics Holdings Ltd6.81m-746.44m4.13bn477.00--2.58--605.92-1.34-1.340.01222.790.0027--0.30213,198.43-29.27---32.86--25.50---10,960.25--9.44--0.1246------16.19------
Alphamab Oncology274.85m-231.63m4.41bn429.00--2.53--16.04-0.2406-0.24060.28551.810.11450.825613.94631,848.10-9.65-18.72-11.16-21.9479.33---84.27-415.554.42--0.167--31.12--35.35---13.12--
Bide Pharmatech Co Ltd1.18bn86.06m4.52bn846.0051.492.10--3.830.89830.898312.2521.980.46080.93594.511,298,144.003.34--3.82--40.11--7.25--4.59--0.0492--30.94---24.94------
Shanghai Aladdin Biochemical Tech Co Ltd535.21m111.53m4.69bn566.0035.394.19--8.760.44390.44391.983.750.31030.38189.08879,345.607.208.838.229.6161.5761.4923.2126.853.10113.470.278145.716.5519.36-7.489.9531.41--
Jiangsu Yahong Meditech Co Ltd160.99m-433.61m4.74bn394.00--2.12--29.47-0.7074-0.70740.26273.650.059816.646.92379,971.80-16.14-15.80-17.15-16.4878.6355.32-269.87-9,445.918.97--0.0599--52,594.79---62.42--64.28--
Beijing Kawin Technol Sha-hld Co Ltd1.53bn144.46m4.96bn584.0033.012.48--3.250.81750.81758.5310.870.57361.803.272,431,971.006.495.318.526.7681.8086.0211.318.102.91--0.14143.8221.7314.8739.7121.0425.01--
Beijing Sun-Novo Pharma Research Co Ltd1.24bn238.05m5.15bn1.39k21.624.23--4.141.981.9810.3310.100.607935.951.77844,377.1011.2512.9918.7621.7053.3053.9318.5021.341.8629.920.306810.7437.7647.2218.0854.9034.77--
Laekna Inc0.00-317.46m5.19bn92.00--7.14-----0.8909-0.89090.001.860.00----0.00-31.46---35.71--------------0.0856------52.81------
Lepu Biopharma Co Ltd220.30m-78.01m5.22bn491.00--5.31383.5923.68-0.0462-0.04620.13230.57440.08471.861.53513,514.70-3.53---5.72--78.76---41.62--0.7322-2.710.4621--1,347.16--96.79------
HitGen Inc455.80m56.51m5.46bn452.0096.473.69--11.990.13140.13141.063.440.2487.104.55937,755.302.994.633.165.1051.2358.8912.0520.6616.1538.230.139119.1412.6419.6961.16-1.96-6.12--
Shanghai Medicilon Inc1.06bn-297.64m5.50bn2.42k--2.17--5.19-2.01-2.017.2317.460.30296.901.27378,525.60-8.529.34-10.6611.730.644336.71-28.1214.932.64--0.114720.18-17.6833.26-109.82--23.60--
GemPharmatech Co Ltd728.37m149.92m6.05bn1.51k40.002.64--8.300.3430.3431.655.200.27034.542.06449,761.405.569.456.3911.1363.0470.2120.5828.164.74--0.050914.6820.4563.48-3.48--141.38--
Data as of Nov 22 2024. Currency figures normalised to Laekna Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.63%Per cent of shares held by top holders
HolderShares% Held
Guotai Asset Management Co., Ltd.as of 30 Jun 20241.13m0.29%
Huashang Fund Management Co., Ltd.as of 30 Jun 2024346.50k0.09%
China Universal Asset Management Co., Ltd.as of 30 Jun 2024202.00k0.05%
GF Fund Management Co., Ltd.as of 30 Jun 2024186.00k0.05%
Lion Fund Management Co., Ltd.as of 30 Jun 2024170.00k0.04%
Great Wall Fund Management Co., Ltd.as of 30 Jun 2024127.16k0.03%
Essence Fund Co., Ltd.as of 30 Jun 2024105.00k0.03%
Bosera Asset Management Co., Ltd.as of 30 Jun 202490.00k0.02%
SSgA Funds Management, Inc.as of 07 Nov 202468.00k0.02%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202435.50k0.01%
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.